For example, CRISPR/Cas9-mediated deletion of two downstream FOXP2 enhancers in the SK-N-MC neuroblastoma cell line leads to impaired expression of FOXP2 and its target genes, whereas deletion of the same enhancers in HEK293 has no effect [40]. The gene discussed is FOXP2; the disease is neuroblastoma.